Member Info for Ralphiebabe

Merry Christmas and a Happy New Year.
???????????

Looks like no more RNS this year.
That’s a wrap ?? Thank you to our partners, shareholders and to our team for your resilience and dedication in 2022, supporting our vision to change the cancer treatment landscape. We'd like to wish you all a Happy Christmas and the very best wishes for the New Year #
https://twitter.com/Physiomics/status/1605913418829103104?s=20&t=CrAgqNfsj74dlO91my3d9g

Looks like Partner news will have to wait till New Year, hopefully good news.
https://twitter.com/Physiomics/status/1605876987066781698?s=20&t=Nev0QZNAROXileboyO_bNQ

Around this time of year Merck renews their contract, could be different this year as mentioned in a previous RNS.

That post now taken off, must have seen their error.

Pathetic what some people will post.

Just seen on Pyc Twitter someone posted that Pyc putting their intention to purchase BioMoti ltd, this was 10 years ago, never came to anything.

Ankyra SITC22.
Last paragraph interesting.
https://www.1stoncology.com/blog/ankyra-therapeutics-presents-positive-preclinical-data-supporting-advancement-of-ank-101-into-clinical-studies-for-treatment-of-solid-tumors1234623772/

ANK-101 administration in NHPs was well tolerated across all dose levels evaluated
Ankyra is currently advancing ANK-101 through Investigational New Drug (IND) enabling studies and plans to submit an IND to the U.S. Food and Drug Administration in the second quarter of 2023

Thought we would have had a group picture at their booth with abstract poster, most of other attendees doing this.

Also presenting today at SITC22.
Posters and Presentations
November 10, 2022 Society for Immunotherapy of Cancer (SITC) Presentation: Anchored immunotherapy with intratumorally administered aluminum hydroxide-tethered IL-12 induces potent anti-tumor immune response

https://ankyratx.com/wp-content/uploads/2022/11/2022-11-03_-SITC-Poster_Battula_final_ID1076.pdf

In response to your tweet message, it was a rollover.

What is Rollover? A rollover means carrying forward your future positions from closing your positions near the expiry date to opening the same new position in a further-out month contract. In simpler words, the process of carrying forward your position from one month to another month is called a rollover.

Tweet site for SITC22
https://twitter.com/hashtag/SITC22?src=hash

Layout of booths page 4, PYC at booth 236.
https://higherlogicdownload.s3.amazonaws.com/SITCANCER/b4133eb1-990b-40ff-b51e-def6e5968513/UploadedImages/SITC_2022_Exhibitor_Prospectus.pdf

Thanks for post Kidlington.
Let’s hope with only 32 participants, they will be a valid and true result.

Nearly full squad attending.
https://twitter.com/Physiomics/status/1585547576216256512?s=20&t=uQ0h5aYJ6YfmkXczuHV_2g

Bit odd these lowish sells last 20 mins.

First day, quite a few people there, no pics of Hayley Close so far.

https://mobile.twitter.com/hashtag/bioeurope

Thanks Kidlington, at least they replied to you and answered some of your questions.

Annual report out and AGM announcement for 22nd November.
https://www.physiomics.co.uk/wp-content/uploads/2022/09/Final-Results-for-the-year-ended-30-June-2022-and-Date-of-AGM_29-09-2022.pdf

Showing net sales of £1 million for 2023, and £1.2 million for 2024 ( with losses decreasing). My take is,that this is contract deals and income from dosing application tool would be extra.
https://www.marketscreener.com/quote/stock/PHYSIOMICS-PLC-32526450/financials/

Maybe to do with following.
https://www.fiercebiotech.com/biotech/numab-raises-111m-to-challenge-genmab-biontech-for-emerging-pd-l1-opportunity

The money will enable Numab to expand development of NM21-1480. Numab began testing its lead candidate, which has a HSA-binding motif to extend its half-life, in humans last year. Once Numab has determined the maximum tolerated dose, it plans to run multiple clinical proof-of-concept trials in different indications in parallel, enabling it to advance quickly in a competitive space.